<DOC>
	<DOCNO>NCT01117480</DOCNO>
	<brief_summary>The purpose study evaluate clinical effectiveness safety adalimumab use routine clinical practice adult participant moderate severe rheumatoid arthritis ( RA ) Canada .</brief_summary>
	<brief_title>Real Life Evaluation Rheumatoid Arthritis Canadians Taking HUMIRA</brief_title>
	<detailed_description>REACH observational survey participant moderate severe rheumatoid arthritis take adalimumab . Participants volunteer ask provide information medical history experience adalimumab . No drug provide result participation registry . All treatment decision independent participation registry .</detailed_description>
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<criteria>Participant eligible take part registry per product monograph . Participants na√Øve adalimumab therapy / participant receive adalimumab therapy le 4 month . Participant moderately severely active RA . Participant inadequate response one Disease Modifying AntiRheumatic Drugs ( DMARDs ) . Participant receive provincial private ( insurance company ) approval adalimumab . Participant able give write informed consent understand survey requirement . Participant traditional DMARD never try . Participant known hypersensitivity adalimumab , component . Participant receive free adalimumab part compassionate program early access drug distribution program . Participant clinically significant concurrent medical psychiatric disorder may influence survey outcome . Participant condition would prevent participation survey completion survey procedures include language limitation possibility participant available period time ( &gt; 12 month ) enrol survey .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2016</verification_date>
	<keyword>Moderate Rheumatoid Arthritis</keyword>
	<keyword>Rheumatoid Arthritis</keyword>
	<keyword>Severe Rheumatoid Arthritis</keyword>
	<keyword>Adalimumab</keyword>
	<keyword>Clinical Effectiveness</keyword>
</DOC>